The invasive fungal infections market is projected to expand significantly by 2034, driven by the anticipated approvals of novel therapies such as ibrexafungerp (GlaxoSmithKline/SCYNEXIS), fosmanogepix (Basilea Pharmaceutica), olorofim (F901318) (Shionogi/F2G), and opelconazole (PC945) (Pulmocide). Their expected use in frontline and combination treatment strategies, rising therapy costs, and improved diagnostic testing that helps identify more IFI patients are likely to accelerate market growth.

LAS VEGAS, Feb. 9, 2026 /PRNewswire/ -- DelveInsight's Invasive Fungal Infections Market Insights report offers a detailed evaluation of current treatment approaches, emerging therapies, individual drug market share, and both current and forecasted market size from 2020 to 2034. The analysis covers major markets including the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Invasive Fungal Infections Market Summary

According to DelveInsight’s assessment, the invasive fungal infections market in the United States was valued at approximately USD 350 million in 2024.

The burden of invasive fungal infections in the United States reached nearly 110,000 cases in 2024, and the number of cases is anticipated to grow during the forecast period (2025–2034).

Among IFIs, invasive candidiasis and aspergillosis represent the largest share of opportunistic infections, predominantly affecting immunocompromised individuals and collectively accounting for nearly 50% of the overall disease burden.

Several pharmaceutical and biotechnology companies—including GlaxoSmithKline, SCYNEXIS, Basilea Pharmaceutica, Shionogi, F2G, Pulmocide, Mycovia Pharmaceuticals, Matinas BioPharma, Biosergen, and Elion Therapeutics—are actively developing innovative therapies for invasive fungal infections. These companies are advancing next-generation antifungal agents that are expected to broaden treatment options and support market growth in the coming years.

Promising therapies currently under clinical development include BREXAFEMME (ibrexafungerp), fosmanogepix, olorofim (F901318), opelconazole (PC945), oteseconazole (VT-1161), MAT2203, SCY-247, BAL2062, BSG005, and EL219 (SF001).

According to DelveInsight’s projections, fosmanogepix is expected to generate the highest revenue among emerging therapies in the United States by 2034.

Discover the new invasive fungal infections treatment @ https://www.delveinsight.com/sample-request/invasive-fungal-infections-market

Key Factors Driving the Growth of the Invasive Fungal Infections Market

Increasing Disease Burden:
The prevalence of invasive fungal infections continues to rise as the number of at-risk populations grows. In the United States alone, approximately 110,000 cases were reported in 2024, and this number is projected to increase during the forecast period.

CRESEMBA (isavuconazonium sulfate) Market Leadership:
CRESEMBA currently leads the invasive fungal infections market, accounting for nearly 45% of the total market share, underscoring its dominance among available oral and intravenous therapies.

Emerging Antifungal Drug Classes:
Several promising therapies are advancing through clinical development. These include BREXAFEMME (ibrexafungerp), an oral triterpenoid active against azole- and echinocandin-resistant Candida species; fosmanogepix, a Gwt1 inhibitor with broad activity against resistant yeasts and molds; olorofim, a DHODH inhibitor targeting azole-resistant Aspergillus; opelconazole, an inhaled azole designed for pulmonary infections; and MAT2203, an oral formulation of amphotericin B designed to reduce toxicity.

First-Mover Advantage of BREXAFEMME (ibrexafungerp):
Within the emerging therapeutic landscape, BREXAFEMME is expected to maintain a strong first-mover advantage in IFIs due to its prior approval for vulvovaginal candidiasis (VVC) and its established clinical experience. Meanwhile, fosmanogepix has the potential to address a broader patient population. Opelconazole, as the first inhaled antifungal therapy, may also improve patient adherence compared with traditional oral or intravenous options.

Invasive Fungal Infections Market Analysis

Managing invasive fungal infections remains challenging due to the limited number of antifungal drug classes, increasing antifungal resistance, and safety concerns associated with current treatments.

Existing treatment options primarily include azoles, echinocandins, polyenes, and flucytosine (5-FC). However, the growing prevalence of multidrug-resistant pathogens such as Candida auris, Candida glabrata, and azole-resistant Aspergillus fumigatus is reducing the effectiveness of these therapies.

Market expansion is being supported by advancements in diagnostic technologies, greater use of antifungal prophylaxis in high-risk patients, and innovation in antifungal drug development and delivery methods.

Late-stage pipeline candidates such as fosmanogepix, ibrexafungerp, and olorofim have the potential to reshape treatment strategies by offering novel mechanisms of action, oral administration options, and improved activity against resistant fungal pathogens.

Despite these advancements, challenges such as toxicity, drug–drug interactions, and ongoing antifungal resistance continue to create unmet medical needs, highlighting the importance of next-generation antifungal therapies in the evolving market.

Invasive Fungal Infections Competitive Landscape

The invasive fungal infections pipeline includes several promising candidates currently in mid- and late-stage clinical development that are expected to reach the market in the coming years. The emerging treatment landscape features diverse therapeutic approaches, including ibrexafungerp (GlaxoSmithKline/SCYNEXIS), fosmanogepix (Basilea Pharmaceutica), olorofim (Shionogi/F2G), and opelconazole (Pulmocide).

Ibrexafungerp, developed by GlaxoSmithKline/SCYNEXIS, is the first agent in a novel class of glucan synthase inhibitors known as triterpenoids. The drug demonstrates broad-spectrum antifungal activity against multiple pathogens, including Candida, Aspergillus, Pneumocystis, dimorphic fungi, and mucorales. It is also effective against multidrug-resistant and pan-resistant strains such as Candida auris. The therapy is already approved for vulvovaginal candidiasis and is currently being evaluated in a Phase III clinical trial (NCT05178862) for invasive candidiasis and other severe fungal infections.

Basilea Pharmaceutica’s fosmanogepix is a first-in-class broad-spectrum antifungal agent that targets the fungal enzyme Gwt1, which plays a key role in fungal cell wall integrity and survival. This novel mechanism enables activity against a wide range of fungal pathogens, including Candida species, Aspergillus, Fusarium, Scedosporium, rare molds, and endemic fungi.

The expected launch of these emerging therapies is likely to significantly transform the invasive fungal infections treatment landscape. As these innovative antifungal drugs progress toward regulatory approval, they are anticipated to establish new standards of care while opening opportunities for continued medical innovation and market expansion.

Discover more about the invasive fungal infections drugs market @ Invasive Fungal Infections Drugs

Recent Developments in the Invasive Fungal Infections Market

In July 2025, Basilea received USD 39 million in funding from BARDA to support the continued development of fosmanogepix.

In May 2025, SCYNEXIS announced the dosing of the first new patient in the Phase III MARIO study following the removal of a previous FDA clinical hold.

In April 2025, BAL2062 completed its Phase I clinical trial, with Phase II development expected to begin in 2026.

In February 2025, Biosergen reported successful treatment completion for the second patient cohort in its proof-of-concept clinical trial evaluating BSG005.

What are Invasive Fungal Infections?

Invasive fungal infections are severe conditions caused by fungal pathogens that invade normally sterile areas of the body, including deep tissues and vital organs. These infections can result in prolonged illness and life-threatening complications.

They primarily affect individuals with compromised immune systems, such as cancer patients receiving chemotherapy, individuals living with HIV/AIDS, and organ transplant recipients receiving immunosuppressive therapy.

Common causative pathogens include Candida species (such as Candida albicans, C. glabrata, and C. tropicalis), Aspergillus species (especially Aspergillus fumigatus), Cryptococcus species, and various dimorphic fungi. Many of these organisms are normally harmless environmental fungi or components of the human microbiota that become pathogenic when the host immune system is weakened.

Invasive Fungal Infections Epidemiology Segmentation

The epidemiology section of the report provides insights into historical and current patient populations as well as future trends across major markets. Approximately 90% of patients eventually develop resistance to first-line antifungal therapy, requiring modifications in treatment strategy.

Among these cases, nearly 30% also develop resistance to second-line therapies, necessitating treatment switches either within drug classes (such as azoles) or across different classes (such as moving from azoles to echinocandins or polyenes).

The invasive fungal infections market report provides epidemiological analysis for the period 2020–2034 across major markets, segmented into:

Total Incident Cases of Invasive Fungal Infections
Total Incident Cases of Invasive Fungal Infections by Type
Total Treatment-eligible Cases of Invasive Fungal Infections
Total Refractory Cases of Invasive Fungal Infections

Invasive Fungal Infections Market Report Metrics

Details

Study Period
2020–2034

Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Invasive Fungal Infections Market CAGR
11.4% (US)

Invasive Fungal Infections Market Size in 2024 (US)
USD 350 Million

Key Invasive Fungal Infections Companies
Glaxosmithkline, SCYNEXIS, Basilea Pharmaceutica, Shionogi, F2G, Pulmocide, Mycovia Pharmaceuticals, Matinas BioPharma, Biosergen, Elion Therapeutics, Cidara Therapeutics, Mundipharma, Astellas Pharma, Pfizer, Vicuron Pharmaceuticals, Mayne Pharma, Merck, and others

Key Invasive Fungal Infections Therapies
BREXAFEMME (ibrexafungerp), Fosmanogepix, Olorofim (F901318), Opelconazole (PC945), Oteseconazole (VT-1161), MAT2203, SCY-247, BAL2062, BSG005, EL219 (SF001), REZZAYO (rezafungin), CRESEMBA (isavuconazonium sulfate), ERAXIS (anidulafungin), TOLSURA (itraconazole), NOXAFIL (posaconazole), and others

Scope of the Invasive Fungal Infections Market Report

Therapeutic Assessment: Invasive Fungal Infections current marketed and emerging therapies
Invasive Fungal Infections Market Dynamics: Key Market Forecast Assumptions of Emerging Invasive Fungal Infections Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Invasive Fungal Infections Market Access and Reimbursement

Download the report to understand the factors driving the invasive fungal infections market @ Invasive Fungal Infections Market Analysis